Breast cancer prevention

Fundamentals of Cancer Prevention

Volumn , Issue , 2005, Pages 255-276

  Thompson, Patricia A ^a   Lopez, Ana Maria ^a   Stopeck, Alison ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880354159     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-26337-3_12     Document Type: Chapter

References (111)

1. (1996). "Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer." Lancet 347(9017): 1713-1727.
2. (2002). "Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial." Lancet 359(9324): 2131-2139.
3. (2002). "Using Medication To Prevent Breast Cancer: Recommendations from the United States Preventive Services Task Force." Ann Intern Med 137(1): 162.
4. ACS (2004). Breast Cancer Facts and Figures 2003-2004, American Cancer Society: http://www.cancer.org/downhads/STT/CAFF2003BrFPWSecured.pdf, accessed 11/20/04.
5. Albert, K.S. and C.M. Gernaat (1984). "Pharmacokinetics of ibuprofen." Am J Med 77(1 A): 40-46.
6. Amir, E., D.G. Evans, et al (2003). "Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme." J Med Genet 40(11): 807-814.
7. Anderson, G.L., M. Limacher, et al (2004). "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial." JAMA 291(14): 1701-1712.
8. Antoine, C, F. Liebens, et al (2004). "Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial." Hum Reprod 19(3): 741-756.
9. Antoniou, A., P.D. Pharoah, et al (2003). "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies." Am J Hum Genet 72(5): 1117-1130.
10. Bolan, P.J., S. Meisamy, et al (2003). "In vivo quantification of choline compounds in the breast with 1H MR spectroscopy." Magn Reson Med 50(6): 1134-1143.
11. Boland, G.P., W.F. Knox, et al (2002). "Molecular markers and therapeutic targets in ductal carcinoma in situ." Microsc Res Tech 59(1): 3-11.
12. Boyd, N.F., G.A. Lockwood, et al (1998). "Mammographic densities and breast cancer risk." Cancer Epidemiol Biomarkers Prev 7(12): 1133-1144.
13. Boyd, N.F., L.J. Martin, et al (2001). "Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention." Curr Oncol Rep 3(4): 314-321.
14. Buist, D.S.M., P.L. Porter, et al (2004). "Factors Contributing to Mammography Failure in Women Aged 40-49 Years." J Natl Cancer Inst 96(19): 1432-1440.
15. Byers, T., M. Nestle, et al (2002). "American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer with Healthy Food Choices and Physical Activity." CA Cancer J Clin 52(2): 92-119.
16. Calderon-Margalit, R. and O. Paltiel (2004). "Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature." Int J Cancer 112(3): 357-364.
17. Calle, E.E., H. Frumkin, et al (2002). "Organochlorines and Breast Cancer Risk." CA Cancer J Clin 52(5): 301-309.
18. Carmichael, A., A.S. Sami, et al (2003). "Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation." European Journal of Surgical Oncology 29(5): 475-479.
19. Cauley, J. A., L Norton, et al (2001). "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation." Breast Cancer Res Treat 65(2): 125-134.
20. Cerhan, J.R., J.D. Potter, et al (2004). "Adherence to the AICR Cancer Prevention Recommendations and Subsequent Morbidity and Mortality in the Iowa Women's Health Study Cohort." Cancer Epidemiol Biomarkers Prev 13(7): 1114-1120.
21. Chlebowski, R.T., M. Pettinger, et al (2004). "Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications." J Clin Oncol 22(22): 4507-4513.
22. Claus, E.B., N. Risch, et al (1991). "Genetic analysis of breast cancer in the cancer and steroid hormone study." Am J Hum Genet 48(2): 232-242.
23. Claus, E.B., M. Stowe, et al (2003). "The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry." The Breast 12(6): 451-456.
24. demons, M., L. Loijens, et al (2000). "Breast cancer risk following irradiation for Hodgkin's disease." Cancer Treatment Reviews 26(4): 291-302.
25. Colditz, G.A. and B. Rosner (2000). "Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study." Am J Epidemiol 152(10): 950-964.
26. Costa, A., F. Formelli, et al (1994). "Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide." Cancer Res 54(7 Suppl): 2032s-2037s.
27. Coyle, Y.M. (2004). "The effect of environment on breast cancer risk." Breast Cancer Res Treat 84(3): 273-288.
28. Davies, G.L. (2003). "Cyclooxygenase-2 and chemoprevention of breast cancer." J Steroid Biochem Mol Biol 86(3-5): 495-499.
29. Decensi, A., D. Serrano, et al (2003). "Breast cancer prevention trials using retinoids." J Mammary Gland Biol Neoplasia 8(1): 19-30.
30. Deligeoroglou, E., E. Michailidis, et al (2003). "Oral Contraceptives and Reproductive System Cancer." Ann NY Acad Sci 997(1): 199-208.
31. Dupont, W.D. and D.L. Page (1985). "Risk factors for breast cancer in women with proliferative breast disease." N Engl J Med 312(3): 146-151.
32. Dupont, W.D., D.L Page, et al (1994). "Long-Term Risk of Breast Cancer in Women with Fibroadenoma." N Engl J Med 331(1): 10-15.
33. Erbas, B., A. Amos, et al (2004). "Incidence of Invasive Breast Cancer and Ductal Carcinoma In situ in a Screening Program by Age: Should Older Women Continue Screening?" Cancer Epidemiol Biomarkers Prev 13(10): 1569-1573.
34. Ernster, V.L., J. Barclay, et al (1996). "Incidence of and treatment for ductal carcinoma in situ of the breast." JAMA 275(12): 913-918.
35. Fisher, B., J.P. Costantino, et al (1998). "Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study." J Natl Cancer Inst 90(18): 1371-1388.
36. Fournier, A., F. Berrino, et al (2004). "Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort." Int J Cancer 114(3):448-454.
37. Gail, M.H., L.A. Brinton, et al. (1989). "Projecting individualized probabilities of developing breast cancer for white females who are being examined annually." J Natl Cancer Inst 81(24): 1879-1886.
38. Gail, M. H., J. P. Costantino, et al (1999). "Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer." J Natl Cancer Inst 91(21): 1829-1846.
39. Gammon, M.D., S.M. Eng, et al (2004). "Environmental tobacco smoke and breast cancer incidence." Environmental Research 96(2): 176-185.
40. Garbe, E., L Levesque, et al (2004). "Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis." Maturitas 47(3): 175-183.
41. Garfinkel, L, C. C. Boring, et al (1994). "Changing trends. An overview of breast cancer incidence and mortality." Cancer 74(1 Suppl): 222-227.
42. Ghafoor, A., A. Jemal, et al (2003). "Trends in Breast Cancer by Race and Ethnicity." CA Cancer J Clin 53(6): 342-355.
43. Giordano, S.H., A.U. Buzdar, et al (2002). "Breast Cancer in Men." Ann Intern Med 137(8): 678-687.
44. Goss, P.E. and K. Strasser-Weippl (2004). "Prevention Strategies with Aromatase Inhibitors." Clin Cancer Res 10(1): 372-379.
45. Haffty, B.G., C. Lee, et al (1998). "Prognostic significance of mammographie detection in a cohort of conservatively treated breast cancer patients." Cancer J Sci Am 4(1): 35-40.
46. Hankinson, S.E., W.C. Willed, et al (1998). "Circulating concentrations of insulin-like growth factor I and risk of breast cancer." Lancet 351(9113): 1393-1396.
47. Harris, R.E., R.T. Chlebowski, et al (2003). "Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative." Cancer Res 63(18): 6096-6101.
48. Hartmann, L.C., D.J. Schaid, et al (1999). "Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer." N Engl J Med 340(2): 77-84.
49. Hemminki, K., R. Rawal, et al (2004). "Mammographie Screening Is Dramatically Changing Age-Incidence Data for Breast Cancer." J Clin Oncol 22(22): 4652-4653.
50. Henderson, B.E. and L Bernstein (1991). "The international variation in breast cancer rates: an epidemiological assessment." Breast Cancer Res Treat 18 (Suppl 1): S11-17.
51. Hodgson, S.V., P.J. Morrison, et al (2004). "Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice." Am J Med Genet 129C(1): 56-64.
52. Hollingsworth, A.B., S.E. Singletary, et al (2004). "Current comprehensive assessment and management of women at increased risk for breast cancer." The American Journal of Surgery 187(3): 349-362.
53. Holmes, M.D. and W.C. Willett (2004). "Does diet affect breast cancer risk?" Breast Cancer Res 6(4): 170-178.
54. Humphrey, L.L., M. Helfand, et al (2002). "Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force." Ann Intern Med 137(5 Part 1): 347-360.
55. Jemal, A., R.C. Tiwari, et al (2004). "Cancer statistics, 2004." CA Cancer J Clin 54(1): 8-29.
56. Jernstrom, H., C. Lerman, et al (1999). "Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2." The Lancet 354(9193): 1846-1850.
57. Johnson, T.W., K.E. Anderson, et al (2002). "Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer." Cancer Epidemiol Biomarkers Prev 11(12): 1586-1591.
58. Kaaks, R. (1996). "Nutrition, hormones, and breast cancer: is insulin the missing link?" Cancer Causes Control 7(6): 605-625.
59. Kelsey, J.L. and L Bernstein (1996). "Epidemiology and prevention of breast cancer." Annu Rev Public Health 17: 47-67.
60. Key, T.J., A. Schatzkin, et al (2004). "Diet, nutrition and the prevention of cancer." Public Health Nutr 7(1 A): 187-200.
61. Kollias, J., I.O. Ellis, et al (1999). "Clinical and histological predictors of contralateral breast cancer." Eur J Surg Oncol 25(6): 584-589.
62. Lacroix, M., R.A. Toulon, et al (2004). "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics." Endocr Relat Cancer 11(3): 497-522.
63. Laden, F. and D.J. Hunter (1998). "Environmental risk factors and female breast cancer." Annu Rev Public Health 19: 101-123.
64. Law, M. (2000). "Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach." Am J Clin Nutr 72(5): 1291-1296.
65. Li, C.I., B.O. Anderson, et al (2002). "Changing incidence of lobular carcinoma in situ of the breast." Breast Cancer Res Treat 75(3): 259-268.
66. Lo, S.S. and V.G. Vogel (2004). "Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs)." Best Practice & Research Clinical Endocrinology & Metabolism 18(1): 97-111.
67. Louie, A.Y., M.M. Huber, et al (2000). "In vivo visualization of gene expression using magnetic resonance imaging." Nat Biotechnol 18(3): 321-325.
68. Moorman, P.G., J.M. Grubber, et al (2003). "Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast." Cancer Causes Control 14(10): 915-922.
69. Morris, E.A., L. Liberman, et al (2003). "MRI of occult breast carcinoma in a high-risk population." Am J Roentgenol 181(3): 619-626.
70. Narod, S.A. and W.D. Foulkes (2004). "BRCA1 and BRCA2: 1994 and beyond." Nature Reviews Cancer 4(9): 665-676.
71. Nayfield, S.G., J.E. Karp, et al (1991). "Potential role of tamoxifen in prevention of breast cancer." J Natl Cancer Inst 83(20): 1450-1459.
72. Nelson, H.D., L.L. Humphrey, et al (2002). "Postmenopausal hormone replacement therapy: scientific review." JAMA 288(7): 872-881.
73. Olsen, J.H., N. Seersholm, et al (1999). "Cancer risk in close relatives of women with early-onset breast cancer - a population-based incidence study." Br J Cancer 79(3-4): 673-679.
74. Page, D.L. (2004). "Breast lesions, pathology and cancer risk." Breast J 10 (Suppl 1): S3-4.
75. Page, D.L. and R.A. Jensen (1994). "Evaluation and management of high risk and premalig-nant lesions of the breast." World J Surg 18(1): 32-38.
76. Parker, E.D. and A.R. Folsom (2003). "Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study." Int J Obes Relat Metab Disord 27(12): 1447-1452.
77. Parkin, D.M. (2004). "International variation." Oncogene 23(38): 6329-6340.
78. Pike, M.C., C.L. Pearce, et al (2004). "Prevention of cancers of the breast, endometrium and ovary." Oncogene 23(38): 6379-6391.
79. Powles, T., R. Eeles, et al (1998). "Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial." Lancet 352(9122): 98-101.
80. Radimer, K.L., R. Ballard-Barbash, et al (2004). "Weight change and the risk of late-onset breast cancer in the original Framingham cohort." Nutr Cancer 49(1): 7-13.
81. Rebbeck, T.R., A.M. Levin, et al (1999). "Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers." J Natl Cancer Inst 91(17): 1475-1479.
82. Ries, L.A.G., M. P. Eisner, et al (2004). SEER Cancer Statistics Review, 1995-2001. Bethesda, MD, National Cancer Institute.
83. Rockhill, B., D. Spiegelman, et al (2001). "Validation of the Gail et al. Model of Breast Cancer Risk Prediction and Implications for Chemoprevention." J Natl Cancer Inst 93(5): 358-366.
84. Rossouw, J.E., G.L. Anderson, et al (2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial." JAMA 288(3): 321-333.
85. Ruffin, M.T.T., D.A. August, et al (1993). "Selection criteria for breast cancer chemoprevention subjects." J Cell Biochem Suppl 17G: 234-241.
86. Sakorafas, G.H., E. Krespis, et al (2002). "Risk estimation for breast cancer development; a clinical perspective." Surg Oncol 10(4): 183-192.
87. Serrano, D., E. Perego, et al (2004). "Progress in chemoprevention of breast cancer." Critical Reviews in Oncology/Hematology 49(2): 109-117.
88. Shen, Q. and P.H. Brown (2003). "Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways." J Mammary Gland Biol Neoplasia 8(1): 45-73.
89. Shi, R., H. Yu, et al (2004). "IGF-I and breast cancer: a meta-analysis." Int J Cancer 111(3): 418-423.
90. Smith, R.A. (2000). "Breast cancer screening among women younger than age 50: a current assessment of the issues." CA Cancer J Clin 50(5): 312-336.
91. Smith, R.A., D. Saslow, et al (2003). "American Cancer Society guidelines for breast cancer screening: update 2003." CA Cancer J Clin 53(3): 141-169.
92. Stankovic, T., A.M. Kidd, et al (1998). "ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer." Am J Hum Genet 62(2): 334-345.
93. Stall, B.A. (1998). "Western diet, early puberty, and breast cancer risk." Breast Cancer Res Treat 49(3): 187-193.
94. Stall, B.A. (1999). "Western nutrition and the insulin resistance syndrome: a link to breast cancer." Eur J Clin Nutr 53(2): 83-87.
95. Sugumar, A., Y.C. Liu, et al (2004). "Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature." Int J Cancer 111(2): 293-297.
96. Terry, M.B., M.D. Gammon, et al (2004). "Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk." JAMA 291(20): 2433-2440.
97. The Women's Health Initiative Steering Committee (2004). "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial." JAMA 291(14): 1701-1712.
98. Thomas, D.B., D.L. Gao, et al (1997). "Randomized trial of breast self-examination in Shanghai: methodology and preliminary results." J Natl Cancer Inst 89(5): 355-365.
99. Tobias, J.S. (2004). "Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention." Ann Oncol 15(12): 1738-1747.
100. Toniolo, P., P.F. Bruning, et al (2000). "Serum insulin-like growth factor-l and breast cancer." Int J Cancer 88(5): 828-832.
101. Tryggvadottir, L, E.J. Olafsdottir, et al (2003). "BRCA2 mutation carriers, reproductive factors and breast cancer risk." Breast Cancer Res 5(5): R121-128.
102. Tyrer, J., S.W. Duffy, et al (2004). "A breast cancer prediction model incorporating familial and personal risk factors." Stat Med 23(7): 1111-1130.
103. Vogel, V.G. (1991). "High-risk populations as targets for breast cancer prevention trials." Preventive Medicine 20(1): 86-100.
104. Vogel, V.G. (2004). "Atypia in the assessment of breast cancer risk: implications for management." Diagn Cytopathol 30(3): 151-157.
105. Ward, E., A. Jemal, et al (2004). "Cancer disparities by race/ethnicity and socioeconomic status." CA Cancer J Clin 54(2): 78-93.
106. Warren Burhenne, L.J., S.A. Wood, et al (2000). "Potential contribution of computer-aided detection to the sensitivity of screening mammography." Radiology 215(2): 554-562.
107. Warren, R. (2004). "Hormones and mammographie breast density." Maturitas 49(1): 67-78.
108. Weissleder, R., A. Moore, et al (2000). "In vivo magnetic resonance imaging of transgene expression." Nat Med 6(3): 351-355.
109. White, S., R. Taetle, et al (1990). "Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects." Cancer Res 50(19): 6295-6301.
110. Wu, K., H.-T. Kim, et al (2002). "Suppression of Mammary Tumorigenesis in Transgenic Mice by the RXR-selective Retinoid, LGD1069." Cancer Epidemiol Biomarkers Prev 11(5): 467-474.
111. Yang, L.M., U.C. Tin, et al (1999). "Role of retinoid receptors in the prevention and treatment of breast cancer." J Mammary Gland Biol Neoplasia 4(4): 377-388.